DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

    Leukemias Epidemiological Global Forecast

    Size markets and assess market potential on a global scale with DRG’s gold-standard epidemiology. DRG epidemiology has the depth and breadth required for accurate market sizing, with 3,400+ patient segmentations across 140+ disease and 40+ countries.

    This report will answer the following key questions:

    • How many people worldwide will be diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) or Chronic myeloid leukemia (CML) in 2017, and how will this number change over the coming decade, and what factors will be driving the change?
    • Which world regions have the greatest number of people diagnosed with AML or ALL or CML in 2017, and which region will show the greatest growth in cases over the coming decade?
    • We report numbers for important subpopulations based on cytogenetics, mutations and which affect therapy and prognosis of Leukemia cases.